Core Memory She's Here To Make Dogs (And Then Humans) Live Longer - EP 40 Celine Halioua
Oct 29, 2025
Celine Halioua, Founder and CEO of Loyal, is revolutionizing pet health with her innovative approach to dog longevity. She shares insights from her groundbreaking clinical trial involving 1,300 dogs aimed at creating a pill that could extend canine lifespans by at least a year. Celine discusses why testing longevity drugs on dogs is advantageous for regulatory approval and the potential to translate findings to humans. With a candid critique of Silicon Valley culture and future aspirations, she brings a pragmatic vision to the longevity biotech landscape.
AI Snips
Chapters
Books
Transcript
Episode notes
Dogs As A Practical Longevity Model
- Loyal chose dogs because their shorter lifespans let companies run definitive longevity trials in years, not decades.
- Dogs share environments and age-related diseases with humans, making results more translatable than mouse studies.
Prioritize Regulator-Friendly Endpoints
- Design trials to meet regulators' efficacy bar first; focus on conditional approval pathways that enable market entry once safety and manufacturing are cleared.
- Build your regulatory story around clear, measurable endpoints like lifespan and quality-of-life assessments.
Running A Massive Decentralized Dog Trial
- Loyal ran a decentralized, FDA-concurred pivotal trial across ~70 U.S. sites and enrolled ~1,300 dogs for lifespan measurement.
- Dogs take a daily pill and are followed for the rest of their lives with vet and owner assessments for quality of life and mortality.
